Get the Stockscreener App
175.64
1.15%
2.12
Biogen Inc stock is traded at $175.64, with a volume of 1.39M.
It is up +1.15% in the last 24 hours and down -5.47% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$173.52
Open:
$172.71
24h Volume:
1.39M
Relative Volume:
1.32
Market Cap:
$25.58B
Revenue:
$9.67B
Net Income/Loss:
$1.16B
P/E Ratio:
9.5612
EPS:
18.37
Net Cash Flow:
$1.47B
1W Performance:
-4.33%
1M Performance:
-5.47%
6M Performance:
-19.30%
1Y Performance:
-29.65%
1-Day Range:
$170.72
$176.70
1-Week Range:
$170.71
$185.00
52-Week Range:
$170.71
$268.30
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts - Investing.com
Biogen Inc. (NASDAQ:BIIB) Holdings Decreased by US Bancorp DE - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Biogen Inc Shares - GuruFocus.com
Biosimilars Market 2024-2031 Market Analysis: Growth Trends, Demand, and Forecast Overview | Biogen Idec Inc - EIN News
Biogen (NASDAQ:BIIB) Price Target Cut to $210.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Biogen stock touches 52-week low at $173.01 amid market challenges - Investing.com Canada
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Wedbush Issues Negative Estimate for Biogen Earnings - MarketBeat
Biogen Analysts Slash Their Forecasts After Q3 Results - MSN
Executive reshuffles: BIIB, USB and WES - MSN
New York State Teachers Retirement System Lowers Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Scrip
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
What is William Blair's Forecast for Biogen Q4 Earnings? - MarketBeat
Biogen, Eisai seek FDA nod for injectable Leqembi (BIIB:NASDAQ) - Seeking Alpha
Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online
Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Eisai, Biogen eye 2025 approval for Leqembi autoinjector - pharmaphorum
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - StockTitan
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status - Biogen | Investor Relations
Roche weighs whether speedy approval path is open for latest Alzheimer’s drug - BioPharma Dive
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter (BIIB) - Seeking Alpha
Biogen Inc (BIIB) Trading Down 3.15% on Oct 31 - GuruFocus.com
Biogen (NASDAQ:BIIB) Reaches New 1-Year LowShould You Sell? - MarketBeat
Biogen's (BIIB) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Biogen stock slips as Morgan Stanley downgrades (BIIB:NASDAQ) - Seeking Alpha
Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online
Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript - Insider Monkey
Recurrent Energy Announces Successful Operation of 134 MW Solar Project - The Manila Times
Biogen shares target lifted by Piper Sandler as diversification strategy unfolds - Investing.com
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating R - GuruFocus.com
Diversify Advisory Services LLC Acquires Shares of 4,719 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Morgan Stanley downgrades Biogen stock as Leqembi launch disappoints - Investing.com
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook - MSN
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... - Yahoo Finance
Biogen Inc. Raises 2024 Financial Outlook Amid Product Launch Success - TipRanks
Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease - TipRanks
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference - Biogen | Investor Relations
Eisai Presents Data on Benefits of Long-Term Administration - GlobeNewswire
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference – Company AnnouncementFT.com - Financial Times
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News
Earnings call: Biogen reports progress and strategic pipeline expansion - Investing.com
Goldman Sachs maintains Buy on Biogen with $290 target - Investing.com
Biogen Announces CFO Transition and Regulation FD Update - TipRanks
Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. - Investor's Business Daily
Leqembi global sales hit $67M, but US adoption remains a challenge - FirstWord Pharma
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View - Yahoo Finance
Biogen and Neomorph enter molecular glue degrader deal - Pharmaceutical Technology
Biogen (BIIB) Q3 2024 Earnings Call Transcript - The Motley Fool
Biogen Exceeds EPS Estimate, Revenue Declines - The Motley Fool
Hints of impatience grow with Biogen as it tries to find a bridge to growth - Endpoints News
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):